Literature DB >> 12450796

Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.

Charles W M Roberts1, Monique M Leroux, Mark D Fleming, Stuart H Orkin.   

Abstract

Recent data suggest the SWI/SNF chromatin remodeling complex may also act as a tumor suppressor. Utilizing a reversibly inactivating conditional allele, we demonstrate that loss of Snf5/Ini1/Baf47/SmarcB1, a core subunit of SWI/SNF, results in highly penetrant cancer predisposition with 100% of mice developing mature CD8(+) T cell lymphoma or rare rhabdoid tumors with a median onset of only 11 weeks. Notably, while loss of Snf5 predisposes to aggressive cancers, it is also required for survival of virtually all nonmalignant cells in vivo. Reversible gene targeting demonstrates a critical and specific role for Snf5 in tumor suppression, provides a novel system in which to explore the genetic pathways involved in tumor suppression by Swi/Snf, and should be of wide use in evaluating other essential tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450796     DOI: 10.1016/s1535-6108(02)00185-x

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  124 in total

1.  Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Authors:  Zainab Jagani; E Lorena Mora-Blanco; Courtney G Sansam; Elizabeth S McKenna; Boris Wilson; Dongshu Chen; Justin Klekota; Pablo Tamayo; Phuong T L Nguyen; Michael Tolstorukov; Peter J Park; Yoon-Jae Cho; Kathy Hsiao; Silvia Buonamici; Scott L Pomeroy; Jill P Mesirov; Heinz Ruffner; Tewis Bouwmeester; Sarah J Luchansky; Joshua Murtie; Joseph F Kelleher; Markus Warmuth; William R Sellers; Charles W M Roberts; Marion Dorsch
Journal:  Nat Med       Date:  2010-11-14       Impact factor: 53.440

Review 2.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

Review 3.  An epigenetic gateway to brain tumor cell identity.

Authors:  Stephen C Mack; Christopher G Hubert; Tyler E Miller; Michael D Taylor; Jeremy N Rich
Journal:  Nat Neurosci       Date:  2016-01       Impact factor: 24.884

Review 4.  Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling.

Authors:  Gang G Wang; C David Allis; Ping Chi
Journal:  Trends Mol Med       Date:  2007-09-05       Impact factor: 11.951

5.  Evaluation of the role of downregulation of SNF5/INI1 core subunit of SWI/SNF complex in clear cell renal cell carcinoma development.

Authors:  Elzbieta Sarnowska; Michal Szymanski; Nataliia Rusetska; Marcin Ligaj; Iga Jancewicz; Pawel Cwiek; Marta Skrodzka; Marcin Leszczynski; Joanna Szarkowska; Alicja Chrzan; Malgorzata Stachowiak; Jaroslaw Steciuk; Anna Maassen; Lech Galek; Tomasz Demkow; Janusz A Siedlecki; Tomasz J Sarnowski
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

6.  Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.

Authors:  Francois Le Loarer; Lei Zhang; Christopher D Fletcher; Agnes Ribeiro; Samuel Singer; Antoine Italiano; Agnes Neuville; Aurélie Houlier; Frederic Chibon; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

7.  BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.

Authors:  Kevin A Link; Craig J Burd; Erin Williams; Thomas Marshall; Gary Rosson; Erin Henry; Bernard Weissman; Karen E Knudsen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Authors:  Gregory R Hoffman; Rami Rahal; Frank Buxton; Kay Xiang; Gregory McAllister; Elizabeth Frias; Linda Bagdasarian; Janina Huber; Alicia Lindeman; Dongshu Chen; Rodrigo Romero; Nadire Ramadan; Tanushree Phadke; Kristy Haas; Mariela Jaskelioff; Boris G Wilson; Matthew J Meyer; Veronica Saenz-Vash; Huili Zhai; Vic E Myer; Jeffery A Porter; Nicholas Keen; Margaret E McLaughlin; Craig Mickanin; Charles W M Roberts; Frank Stegmeier; Zainab Jagani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

9.  CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis.

Authors:  Lu Wang; Zibo Zhao; Mark B Meyer; Sandeep Saha; Menggang Yu; Ailan Guo; Kari B Wisinski; Wei Huang; Weibo Cai; J Wesley Pike; Ming Yuan; Paul Ahlquist; Wei Xu
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743

Review 10.  Chromatin-modifying enzymes as therapeutic targets--Part 2.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.